PS
SKYE icon

Principal Securities’s Skye Bioscience SKYE Stock Holding History

Principal Securities’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2
Closed -$6 – 3903
2025
Q1 		$6 Hold
2
– – ﹤0.01% 3549
2024
Q4 		$6 Hold
2
– – ﹤0.01% 3544
2024
Q3 		$8 Hold
2
– – ﹤0.01% 3431
2024
Q2 		$16 Buy
+2
New +$24 ﹤0.01% 3383

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Principal Securities's SKYE Position: Q2 2025 in Review

Principal Securities sold out of Skye Bioscience (SKYE) in Q2 2025, closing a stake of 2 shares — an estimated $6 sold.

Principal Securities first reported a position in SKYE in Q2 2024 and held it in 4 quarters. The position peaked at $16 in Q2 2024. 58 funds tracked by Wall St. Rank hold SKYE as of Q2 2025.

  • Principal Securities reported no remaining Skye Bioscience position as of Q2 2025 after selling out during the quarter.
  • Principal Securities sold 2 Skye Bioscience shares in Q2 2025, an estimated $6.
  • Principal Securities first reported a position in Skye Bioscience in Q2 2024 and held it in 4 quarters.
  • Principal Securities's Skye Bioscience position peaked at $16 in Q2 2024.
  • 58 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2025.

Based on Principal Securities's 13F filing for Q2 2025, filed 11 Aug 2025.